LCOR, an East Coast multifamily developer, has acquired a 309 East 94th Street property on Manhattan's Upper East Side from Taconic Partners for $73 million. The 87,000-square-foot assemblage marks another exit for Taconic from its life sciences portfolio in New York City.
The transaction reflects a significant strategic shift in how developers are viewing Manhattan real estate, particularly in the life sciences sector. Taconic has been systematically divesting life sciences projects across the city as market conditions tighten and biotech funding landscapes shift. This Upper East Side sale represents another chapter in that broader retreat.
LCOR's entry into this particular site signals confidence in the multifamily residential market on the Upper East Side despite broader economic headwinds. The developer has built its reputation developing apartment buildings across the East Coast and recently expanded into South Florida's residential market, where strong population migration and housing demand have created opportunities. The UES acquisition suggests LCOR sees similar potential in one of Manhattan's most established residential neighborhoods.
The $73 million price point for the 87,000-square-foot assemblage values the land at approximately $839 per square foot. For context, this reflects the cost-of-entry for Manhattan residential development, where developers must factor in significant construction, permitting, and financing costs before delivering units to market. Upper East Side development typically commands higher per-unit economics than other neighborhoods due to the area's brand, infrastructure, and tenant demographics.
For the multifamily market, this deal underscores how rapidly priorities have shifted post-pandemic. Life sciences projects that seemed attractive during the biotech boom have lost luster as venture capital dried up and biotech companies deferred expansion plans. Property owners holding speculative life sciences sites have accelerated sales to buyers with different use cases. Residential development offers more predictable demand metrics and established financing pathways through conventional construction lending.
For potential apartment renters in the area, the conversion could mean new supply hitting an Upper East Side market that has remained relatively tight compared to other Manhattan neighborhoods. LCOR will need to navigate the complex path of planning approvals, design, financing, and construction before delivering units. The Upper East Side's community board and local elected officials will scrutinize any major development proposal. The timeline from acquisition to occupancy typically spans four to seven years for a Manhattan multifamily project.
Taconic's decision to sell reflects realistic asset management during a challenging period for speculative real estate. The firm still maintains significant portfolio holdings but has recognized that timing matters. Selling now rather than holding life sciences assets that may take years to repurpose creates liquidity when capital remains relatively expensive.
Financing for LCOR's development will prove critical. Construction lenders have tightened terms significantly since 2022. Debt availability and interest rates have constrained many multifamily projects, though institutional developers with track records like LCOR have better access to capital than smaller competitors. The developer's recent South Florida entry suggests sufficient capital reserves and lending relationships to underwrite this Manhattan play.
The Upper East Side remains one of Manhattan's most resilient neighborhoods for residential development, with strong employment corridors nearby and established schools. LCOR's acquisition positions the developer to capitalize on Manhattan's ongoing structural demand for quality rental housing among high-income tenants.